Novel ADCs, specifically sacituzumab govitecan and fam-trastuzumab deruxtecan-nxki (an HER2-directed antibody and topoisomerase inhibitor conjugate), have recently obtained FDA approval for patients with metastatic TNBC and metastatic HER2 positive breast cancer, respectively [167, 176, 177]. The gene discussed is ERBB2; the disease is breast carcinoma.